Senior Full Stack Engineer 1

YPrime wins two Clinical Trials Arena Excellence Awards for innovation in AI and sustainable eCOA practices. MALVERN, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) - YPrime, a proven leader in clinical trial technology, today announced it has received two distinctions in the 2025 Clinical Trials Arena Excellence Awards: Innovation for AI in Clinical Trials and Environmental Excellence for Sustainable Trials. Powered by GlobalData's independent research, the Clinical Trials Arena Excellence Awards recognize organizations advancing meaningful progress across the clinical research ecosystem. "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more..." "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more..." "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." YPrime earned recognition for two standout initiatives: its pioneering application of artificial intelligence (AI) to accelerate eCOA localization, and its company-wide efforts to embed sustainability into clinical trial workflows - from digital-first product design to measurable reductions in environmental footprint. The honors reflect YPrime's continued commitment to advancing trial efficiency, data quality, and global participation through responsible, future-focused technology. AI Innovation: Solving a Persistent Bottleneck in eCOA Localization The Innovation Award recognizes YPrime's work applying domain-specific AI to one of the most overlooked drivers of delay in global clinical trials, the migration of translated Clinical Outcome Assessments (COAs) into eCOA platforms. Traditionally a manual, error-prone step, migration requires aligning complex file structures, HTML tag logic, and linguistic formatting across dozens of languages - often prompting multiple rounds of reproofing and introducing costly delays to study startup. YPrime reframed the challenge by automating the migration step itself. Its AI migration engine is trained on YPrime's proprietary file structures and tagging logic, enabling precise alignment of text, tags, and formatting before human review. In a comparative analysis of 15 studies across 11 languages, YPrime's AI-enabled workflow delivered measurable gains, including: * 74% fewer migration errors * 60% fewer screen reports requiring rework * 67% faster localization review cycles * 0 new error types introduced by AI "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," said Jonathan Norman, Director of Localization & Scale Management at YPrime. "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more languages, and collect cleaner, more representative data." Environmental Leadership: Sustainable Trials by Design YPrime also received the Clinical Trials Arena Environmental Excellence Award for embedding sustainability into clinical trial execution. The company's digital-first platforms - eCOA, IRT, and eConsent - replace paper-based processes, reduce site-dependent workflows, and minimize shipments and travel. Over multiple years, these product decisions, coupled with operational changes, have driven measurable progress: * 87% reduction in printed trial documents over three years * 100% reuse or recycling of clinical trial devices through circularity programs * Zero Scope 1 emissions achieved, with reductions across Scope 2 and 3 * Sustainability integrated into supplier oversight, including a Supplier Code of Conduct * EcoVadis Bronze and CDP "B" ratings achieved in 2024 "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," said Ian Lennox, CEO of YPrime. "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable practices must go hand in hand. These awards recognize the work of our teams and partners who are helping build a more responsible, inclusive future for clinical research." These dual awards show YPrime's leadership, following recent launches such as Advanced eCOA Oversight, Automated Data Change Forms (DCF), connected device integrations, and YPrime's industry-leading approach to AI-supported eCOA localization. YPrime was also named a Leader in the Everest Group 2025 eCOA PEAK Matrix(R) Assessment and recognized as a Trailblazer in Patient Engagement. To learn more about YPrime's award-winning innovations and global clinical technology solutions, visit www.yprime.com, or Clinical Trials Arena. About YPrime YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance with an intuitive app and easy-to-use design, streamlines site workflows through a powerful eCOA portal, integrates seamlessly with connected devices, and supports sponsors with dashboards for better decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA and IRT deliver faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime blends deep industry expertise and innovation to deliver reliable solutions. With nearly two decades of proven success, solutions in 250+ languages, and support in 100+ countries, YPrime is your partner to solve clinical research challenges with certainty. Visit www.yprime.com or email [email protected]. About GlobalData GlobalData Plc (AIM: DATA) is a leading data, insights, and analytics platform that delivers trusted proprietary insights and tailored intelligence solutions for the world's largest industries. The company's mission is to help clients decode the future, make better decisions, and reach more customers. By combining proprietary data with human expertise and powerful AI, GlobalData provides next-generation intelligence through one connected platform. For more information, visit https://www.globaldata.com. Media Contact Grazia Mohren Senior Vice President, Marketing, YPrime [email protected]

YPrime launches Advanced eCOA Oversight to strengthen investigator accountability and participant safety. MALVERN, PA - October 29, 2025 - YPrime, a proven leader in clinical trial technology, today announced the launch of its Advanced eCOA Oversight functionality - a key enhancement to its eCOA platform designed to simplify and strengthen how Principal Investigators (PIs) review and acknowledge participant data. Recent updates from the EMA Guideline on Computerized Systems[1] and ICH E6(R3)[2] emphasize that investigator oversight must be documented, attributable, and demonstrable, including electronic review and endorsement of study data at predetermined milestones. These frameworks reinforce the investigator's responsibility to maintain data integrity, ensure participant safety, and confirm the accuracy and completeness of data submitted to sponsors. YPrime's Advanced eCOA Oversight addresses these evolving regulatory expectations by embedding a compliant, auditable signature workflow directly into the eCOA platform. * Attributable Signatures: Each electronic sign-off is securely tied to the individual investigator, maintaining 21 CFR Part 11 compliance. * Re-Signature Capability: When data is changed after prior sign-off, the system automatically prompts the PI to review and re-sign, ensuring data continuity and traceability. * Demonstrable Oversight: Investigators can review and acknowledge participant data at their convenience within the eCOA platform. * Audit-Ready Reporting: Oversight reports capture electronic data review, signature history, timestamps, and data changes for inspection or submission. "YPrime's Advanced eCOA Oversight represents the next evolution of our eCOA platform - giving investigators and sponsors greater visibility, faster access to verified data, and a more efficient path to study delivery," said Ian Lennox, Chief Executive Officer at YPrime. "It's a strong example of how we continue to anticipate what sites and regulators need, while enabling trials to run with greater confidence and control." By digitizing the PI acknowledgment process, YPrime eliminates the need for manual print-and-sign workflows that have long burdened clinical research sites. Investigators can now fulfill their regulatory responsibilities within a single, secure system that records every review and endorsement in real time. "Regulatory agencies are making it clear that investigator oversight must be traceable, attributable, and electronic," said Aubrey Verna, Senior Product Director of eCOA at YPrime. "This feature ensures those expectations are met, streamlining oversight while maintaining the highest levels of compliance and data integrity." This launch extends YPrime's commitment to innovation that accelerates compliance and operational excellence, while improving the experience for participants and sites. Recent eCOA enhancements - including YPrime's AI-powered eCOA localization, Automated Data Change Forms (DCF), and glucometer integrations - underscore the company's mission to advance science and health by simplifying clinical trials, empowering sponsors to launch faster, with high quality data, and stronger participant engagement. YPrime was recently named a Leader in Everest Group's 2025 eCOA PEAK Matrix(R) Assessment, recognizing the company's proven ability to deliver scalable, high-quality eCOA solutions that meet the speed and complexity of today's global clinical trials. This latest release builds on that leadership, demonstrating YPrime's continued investment in clinical trial innovation. YPrime was also previously recognized as a Trailblazer in Patient Engagement by Everest Group in 2024, underscoring its commitment to creating digital tools that make clinical trials more intuitive, patient-centered, and efficient. About YPrime YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance with an intuitive app and easy-to-use design, streamlines site workflows through a powerful eCOA portal, integrates seamlessly with connected devices, and supports sponsors with dashboards for better decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA and IRT deliver faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime blends deep industry expertise and innovation to deliver reliable solutions. With nearly two decades of proven success, solutions in 250+ languages, and support in 100+ countries, YPrime is your partner to solve clinical research challenges with certainty. Visit www.yprime.com or email [email protected]. Media Contact Grazia Mohren Senior Vice President, Marketing, YPrime [email protected]